文献速递糖尿病肥胖与代谢综合征

小鼠Cideb敲低通过质膜sn-1,2-DAGs-PKCε-IRKT1150通路增加线粒体脂肪氧化并逆转肝脂肪变性和胰岛素抵抗

Cideb knockdown in mice increases mitochondrial fat oxidation and reverses hepatic steatosis and insulin resistance by the plasma membrane sn-1,2-DAGs-PKCε-insulin receptor kinaseT1150 pathway.
PubMed 文献 · Diabetologia · 2025-09-04

该研究在高脂饮食小鼠模型中,用反义寡核苷酸敲低Cideb,发现可增加全身能量消耗约25%、降低肝脏甘油三酯约65%,并改善胰岛素抵抗。机制涉及增加肝脏线粒体氧化、减少脂肪生成,以及降低质膜sn-1,2-DAGs-PKCε-IRKT1150磷酸化。提示Cideb敲低可能成为MASLD和2型糖尿病的新治疗策略。

要点

  • Cideb敲低增加高脂饮食小鼠全身能量消耗约25%,降低肝脏甘油三酯约65%。
  • Cideb敲低改善胰岛素抵抗,与降低质膜sn-1,2-DAGs-PKCε-IRKT1150磷酸化相关。
  • Cideb敲低减少肝脏脂肪主要归因于线粒体氧化增加和脂肪生成减少。

核心结论

  • Cideb敲低可增强线粒体脂肪氧化并减少肝脏脂肪生成,从而通过质膜sn-1,2-DAGs-PKCε-IRKT1150通路减轻高脂饮食诱导的肝脂肪变性和胰岛素抵抗。

研究设计与样本

  • C57BL/6J雄性小鼠喂食高脂饮食以模拟MASLD和肝脏胰岛素抵抗,使用2'-O-甲氧基乙基反义寡核苷酸敲低Cideb。
  • 采用Q-Flux评估肝脏线粒体糖异生和三羧酸循环通量,CLAMS评估全身能量消耗,高胰岛素-正葡萄糖钳夹结合放射性同位素评估肝脏和外周胰岛素敏感性。

主要发现

  • 与野生型小鼠相比,Cideb反义寡核苷酸治疗使高脂饮食MASLD小鼠全身能量消耗增加约25%,肝脏甘油三酯降低约65%。
  • Cideb敲低减少肝脏脂肪含量,主要归因于肝脏线粒体氧化速率增加和肝脏脂肪生成减少。
  • Cideb敲低改善高脂饮食诱导的胰岛素抵抗,归因于肝脏和骨骼肌中质膜sn-1,2-DAGs-PKCε-IRKT1150磷酸化降低。

临床怎么用

  • Cideb敲低通过增加线粒体脂肪氧化和减少肝脏脂肪生成改善肝脂肪变性和胰岛素抵抗,提示其作为MASLD和2型糖尿病新型治疗靶点的潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: CIDEB (cell death-inducing DFF45-like effector B) deficiency is associated with a reduced incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) in humans; however, the underlying mechanism responsible for this protective effect remains unclear. METHODS: C57BL/6J male mice were fed a high-fat diet (HFD) to recapitulate key aspects of MASLD and hepatic insulin resistance. Cideb knockdown (KD) was achieved using a 2'-O-methoxyethyl (MOE) antisense oligonucleotide (ASO). In vivo rates of hepatic mitochondrial gluconeogenesis and tricarboxylic acid (TCA) cycle flux were assessed by Q-Flux. The Comprehensive Lab Animal Monitoring System (CLAMS) was used to evaluate rates of whole-body energy expenditure. Hepatic and peripheric insulin sensitivity were evaluated using hyperinsulinaemic-euglycaemic clamp studies combined with radio-labelled isotopes. RESULTS: We showed that Cideb ASO treatment increased rates of whole-body energy expenditure by ~25% and decreased hepatic triacylglycerol by ~65% in a HFD mouse model of MASLD compared with the wild-type mice. Cideb KD reduced hepatic fat content, which could mostly be attributed to increased rates of hepatic mitochondrial oxidation, in combination with reduced hepatic lipogenesis. Additionally, Cideb KD ameliorated HFD-induced insulin resistance, which could be attributed to decreased plasma membrane sn-1,2-diacylglycerols (DAGs)-protein kinase C (PKC)ε-insulin receptor kinase (IRK)T1150 phosphorylation in liver and skeletal muscle. CONCLUSIONS/INTERPRETATION: These findings demonstrate that Cideb KD enhances mitochondrial fat oxidation and reduces hepatic lipogenesis, which in turn mitigates HFD-induced hepatic steatosis and insulin resistance via the plasma membrane sn-1,2-DAGs-PKCε-IRKT1150 pathway, highlighting its potential as a novel therapeutic approach for MASLD and type 2 diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Zheng J, Gaspar RC, Sakuma I, et al. Cideb knockdown in mice increases mitochondrial fat oxidation and reverses hepatic steatosis and insulin resistance by the plasma membrane sn-1,2-DAGs-PKCε-insulin receptor kinaseT1150 pathway. Diabetologia. 2025. PMID: 40908405. doi:10.1007/s00125-025-06539-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。